← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
New York Stem Cell Foundation
New York, NY
$5,447,546
Total funding
4
Grants
Funding over time
peak $1.6M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,447,546 · 4
By mechanism
R01$4,150,732 · 1
R21$1,147,314 · 2
N01$149,500 · 1
Investigators at New York Stem Cell Foundation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2019 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2021 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2022 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$877,246
R01 · FY2020 · AG
Use of iPSC systems to define roles of microglial TREM2/DAP12 and CR3/DAP12 complexes and their genetic variants in specifying risk for late onset sporadic Alzheimer's disease$641,748
R01 · FY2018 · AG
Investigating the biology of human neurotoxic reactive astrocytes using induced pluripotent stem cells$520,914
R21 · FY2019 · NS
Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections$234,900
R21 · FY2020 · CA
Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections$195,750
R21 · FY2019 · CA
Establishing efficient technologies for ovarian cancer organoid derivation from fresh tumor resections$195,750
R21 · FY2021 · CA
THE PURPOSE OF THIS MODIFICATION IS TO CREATE ISOGENIC CELL CONTROL LINES FOR THE LINES CURRENTLY BEING CREATED.$149,500
N01 · FY2021 · OD